-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Tourmaline Bio, Maintains $70 Price Target

Benzinga·05/05/2025 11:01:57
Listen to the news
Chardan Capital analyst Daniil Gataulin maintains Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $70 price target.